Taken together, these studies demonstrate the marked efficacy and apparent tolerability of CTX-MMAE in models of PaCa that differ in expression of the target receptor EGFR. The gene discussed is EGFR; the disease is permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome.